MedPath

Treatment of chronically depressed patients: a multisite randomised controlled trial testing the effectiveness of ‘Cognitive Behavioral Analysis System of Psychotherapy’ (CBASP) for chronic depressions versus usual secondary care.

Recruiting
Conditions
Treatment of Chronic depression (Behandeling van Chronische depressie).
Registration Number
NL-OMON24823
Lead Sponsor
GGZBuitenamstelMentrumPsyQ
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
160
Inclusion Criteria

Patients (aged 18-65) are eligible to participate if their main diagnosis is a chronic form of depression according the DSM-IV criteria:

1. a chronic depressive disorder (i.e. existing for longer than 2 years);

Exclusion Criteria

Patients are excluded from the study if:

1. they suffer from one (or more) of the following disorders: a psychotic disorder, bipolar disorder, organic brain syndrome, severe substance or alcohol dependence, or a severe borderline, schizotypical, or antisocial personality disorder;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome measure is the reduction of depressive symptoms measured with the 28-item version of Inventory of Depressive Symptoms (IDS). The IDS is a measure of symptom severity in depression that has been used to assess acute and longer-term outcomes and has highly acceptable psychometric properties (Cronbach’s alpha = .92). The IDS self-report version will be administered at baseline, after 8, 16 and 32 weeks and at the end of the study, at 52 weeks follow-up. Patients with a symptom reduction of 50%, measured on the IDS, can be seen as responder. Remission is defined as an IDS score of 13 or less.<br><br /><br /><br>In addition, the Quick Inventory for Depressive Symptomatology (QIDS), a shortened version of 16-items of the IDS, will be administered monthly during the study. Internal consistency is high for the QIDS (Cronbach’s alpha = .86), and the total scores were highly correlated (.96) with the total scores of the IDS. <br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath